Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping ...

Fresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations for its lead immuno-oncology drug. The Irish-American biotech picked up the ...